Management issues for women with epilepsy: Neural tube defects and folic acid supplementation

Neurology

Volumn 61, Issue 6 SUPPL. 2, 2003, Pages

  Yerby, Mark S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FOLIC ACID; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARNOLD CHIARI MALFORMATION; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPILEPSY; FEMALE; FETUS; HUMAN; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; NONHUMAN; NUTRITIONAL DEFICIENCY; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENICITY; VITAMIN SUPPLEMENTATION;

EID: 0141765764     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.61.6_suppl_2.s23     Document Type: Review

References (53)

1. Mullers-Kuppers VM. Embryopathy during pregnancy caused by taking anticonvulsants. Acta Paedopsychiatr 1963;30:401-405.
2. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972;2:839-843.
3. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. BMJ 1973;2:442-448.
4. Kelly TE. Teratogenicity of anticonvulsant drugs I: review of the literature. Am J Med Genet 1984;19:413-434.
5. Nakane Y, Oltuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of anticonvulsants: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-680.
6. Battino D, Binelli S, Caccamo ML, et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand 1992;85:204-207.
7. Philbert A, Dam M. The epileptic mother and her child. Epilepsia 1982;23:85-99.
8. Steegers-Theunissen RP, Reiner WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcomes in epileptic women: a multicenter prospective study. Epilepsy Res 1994;18:261-269.
9. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997;17:561-564.
10. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158.
11. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937. Letter.
12. Rosa F. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
13. Little BB, Santos-Ramos R, Newell JF, Maderry MC. Megadose carbamazepine during the period of neural tube closure. Obstet Gynecol 1993;82(4 pt 2 suppl):705-708.
14. Kallen B. Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994;8:203-205.
15. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42(suppl 5):111-118.
16. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986;1:1392-1393.
17. Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology 1992;42(suppl 5):8-11.
18. Omtzigt JG, Las FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-125.
19. Mulinare J, Erickson D. Prevention of neural tube defects. Teratology 1997;56:17-18.
20. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LYC. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285:2981-2986.
21. Van Allen MI, Kalousek DK, Chernoff GF, et al. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet 1993;47:723-743.
22. Golden JA, Chernoff GF. Multiple sites of anterior neural tube closure in humans: evidence from anterior neural tube defects (anencephaly). Pediatrics 1995;95:506-510.
23. Seller MJ. Recent developments in the understanding of the aetiology of neural tube defects. Clin Dysmorphol 1995;4:93-104.
24. Harris JA, Shaw GM. Neural tube defects - why are rates high among populations of Mexican descent? Environ Health Perspect 1995;103(suppl 6):163-164.
25. Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 1990;85:1-9.
26. Blatter BM, Roeleveld N, Zielhuis GA, Mullaart RA, Gabreels FJM. Spina bifida and prenatal occupation. Epidemiology 1996;7:188-193.
27. Matte TD, Mulinare J, Erickson JD. Case-control study of congenital defects and parental employment in health care. Am J Ind Med 1993;24:11-23.
28. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996;275:1089-1092.
29. Dansky LV, Andermann E, Andermann F, Sherwin AL, Kinch RA. Maternal epilepsy and congenital malformations: correlation with maternal plasma anticonvulsant levels during pregnancy. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982:251-258.
30. Zhu MX, Zhou SS. Reduction of the teratogenic effects of phenytoin by folic acid and a mixture of folic acid, vitamins, and amino acids: a preliminary trial. Epilepsia 1989;30:246-251.
31. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsant drugs. Eur J Obstet Gynecol Reprod Biol 1984;18:211-216.
32. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Ann Pharmacother 1998;32:802-817.
33. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983;1:1027-1031.
34. Seller MJ, Nevin NC. Periconceptional vitamin supplementation and the prevention of neural tube defects in south-east England and Northern Ireland. J Med Genet 1984;21:325-330.
35. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-3145.
36. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989;262:2847-2852.
37. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137.
38. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-1835.
39. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257-1261.
40. Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999;8:253-254.
41. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001;42:750-753.
42. Hansen DK, Grafton TF. Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro. Teratology 1991;43:575-582.
43. Hansen DK, Grafton TF, Dial SL, Gehring TA, Siitonen PH. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Teratology 1995;52:277-285.
44. Mills JL, Tuomilehto J, Yu KF, et al. Maternal vitamin levels during pregnancies producing infants with neural tube defects. J Pediatr 1992;120:863-871.
45. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ (Clin Res Ed) 1981;282:1509-1511.
46. Winship KA, Cahal DA, Weber JCP, Griffin JP. Maternal drug histories and central nervous system anomalies. Arch Dis Child 1984;59:1052-1060.
47. Vergel RG, Sanchez LR, Heredero BL, Rodrigez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990;10:149-152.
48. Kirke PN, Daly LE, Elwood JH. A randomized trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group. Arch Dis Child 1992;67:1442-1446.
49. Bower C, Stanley FJ. Periconceptional vitamin supplementation and neural tube defects: evidence from a case-control study in Western Australia and a review of recent publications. J Epidemiol Community Health 1992;46:157-161.
50. Freil JK, Frecker M, Fraser FC. Nutritional patterns of mothers of children with neural tube defects in Newfoundland. Am J Med Genet 1995;55:195-199.
51. Davis BA, Bailey LB, Gregory JF, Toth JP, Dean J, Stevenson RE. Folic acid absorption in women with a history of pregnancy with neural tube defect. Am J Clin Nutr 1995;62:782-784.
52. Oakley GP. Folic-acid-preventable spina bifida and anencephaly. Bull WHO 1998;76(suppl 2):116-117.
53. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992;41(RR-14):1-7.